{"id":44,"date":"2024-10-21T00:17:14","date_gmt":"2024-10-20T22:17:14","guid":{"rendered":"https:\/\/semmelweis.hu\/tumorimmune\/?page_id=44"},"modified":"2026-03-26T09:20:10","modified_gmt":"2026-03-26T08:20:10","slug":"kutatas","status":"publish","type":"page","link":"https:\/\/semmelweis.hu\/tumorimmune\/kutatas\/","title":{"rendered":"Kutat\u00e1s"},"content":{"rendered":"<h5>Tartalomjegyz\u00e9k:<\/h5>\n<ul>\n<li><a href=\"#tumor-mikrokornyezet\">Tumor mikrok\u00f6rnyezet felt\u00e9rk\u00e9pez\u00e9se in situ technik\u00e1kkal t\u00fcd\u0151r\u00e1kban<\/a><\/li>\n<li><a href=\"#bel-mikrobiom\">A b\u00e9l mikrobiom hat\u00e1sa a tumorellenes immunit\u00e1sra \u00e9s az immunter\u00e1pi\u00e1ra<\/a><\/li>\n<li><a href=\"#eszkozok\">Eszk\u00f6z\u00f6k, m\u00f3dszerek<\/a><a id=\"tumor-mikrokornyezet\"><\/a><\/li>\n<\/ul>\n<h2>Tumor mikrok\u00f6rnyezet felt\u00e9rk\u00e9pez\u00e9se in situ technik\u00e1kkal t\u00fcd\u0151r\u00e1kban<\/h2>\n<div class=\"keretes w-100\">\n<p><span style=\"font-weight: 400; font-size: 14pt;\">A t\u00fcd\u0151r\u00e1k \u00e9s annak leggyakoribb v\u00e1ltozata, a nem kissejtes t\u00fcd\u0151r\u00e1k (NSCLC), tov\u00e1bbra is az egyik vezet\u0151 hal\u00e1lok a daganatos betegs\u00e9gek k\u00f6z\u00f6tt vil\u00e1gszerte. Az immunter\u00e1pi\u00e1k, k\u00fcl\u00f6n\u00f6sen az immunellen\u0151rz\u0151pont-g\u00e1tl\u00f3k (ICI) ter\u00e9n el\u00e9rt el\u0151rel\u00e9p\u00e9sek ellen\u00e9re a jelenlegi kezel\u00e9sek hat\u00e9konys\u00e1ga korl\u00e1tozott, \u00e9s a megl\u00e9v\u0151 biomarkerek, mint a PD-L1 expresszi\u00f3 \u00e9s a tumor mut\u00e1ci\u00f3s terhel\u00e9se (tumor mutation burden, TMB) predikt\u00edv ereje nem kiel\u00e9g\u00edt\u0151. A kutat\u00e1si projekt c\u00e9lja olyan \u00faj sz\u00f6veti biomarkerek felfedez\u00e9se, amelyek jobban meg tudj\u00e1k j\u00f3solni, hogyan reag\u00e1l egy beteg az immunter\u00e1pi\u00e1ra.<\/span><\/p>\n<\/div>\n<p><span style=\"font-weight: 400; font-size: 14pt;\">Az elm\u00falt \u00e9vtizedben a daganatok mikro-k\u00f6rnyezete (tumor micro-environment, TME) a daganatbiol\u00f3gia egyik legfontosabb r\u00e9sz\u00e9v\u00e9 v\u00e1lt. A tudom\u00e1nyos adatok szoros kapcsolatot mutatnak bizonyos immunsejt-popul\u00e1ci\u00f3k intratumor\u00e1lis s\u0171r\u0171s\u00e9ge \u00e9s a betegek t\u00fal\u00e9l\u00e9se \u00e9s ter\u00e1pi\u00e1s v\u00e1lasza k\u00f6z\u00f6tt. A CD8+ citotoxikus T-sejtek a tumorellenes v\u00e9dekez\u00e9s f\u0151 v\u00e9grehajt\u00f3i, mivel specifikusan t\u00e1madj\u00e1k a tumorsejteket, hossz\u00fa t\u00e1v\u00fa v\u00e9delmet biztos\u00edtva. A velesz\u00fcletett immunsejtek (ILC-k) k\u00f6zvetlen\u00fcl \u00e9s k\u00f6zvetetten is szab\u00e1lyozz\u00e1k a TME-t, m\u00edg az NK sejtek \u00e9s a \u03b3\u03b4 T-sejtek k\u00f6zvetlen\u00fcl puszt\u00edtj\u00e1k a tumorsejteket. A Treg-ek, az MDSC-k \u00e9s az M2-szer\u0171 TAM-ok pedig pro-tumor hat\u00e1s\u00fa immunsejtek. A CD8+ T-sejtek infiltr\u00e1ci\u00f3j\u00e1t a TAM-ok \u00e9s Treg-ek is befoly\u00e1solj\u00e1k, amelyek a tumorsejtek t\u00fal\u00e9l\u00e9s\u00e9t \u00e9s prolifer\u00e1ci\u00f3j\u00e1t seg\u00edthetik. A T-sejtek azonban hajlamosak kimer\u00fclni az immunszuppressz\u00edv TME-ben, \u00edgy a sejts\u0171r\u0171s\u00e9g \u00e9s ar\u00e1nyok nem mindig t\u00fckr\u00f6zik h\u0171en a daganatellenes immunv\u00e1laszt. Az immun-ellen\u00f6rz\u0151pontok (immune-checkpoints, PD-L1, CTLA-4) \u00e9s a CD8+ T-sejteken tal\u00e1lhat\u00f3 kimer\u00fclts\u00e9gi (exhaustion) markerek (PD1, LAG3, TIM3, TIGIT) tov\u00e1bbi \u00e9rt\u00e9kes inform\u00e1ci\u00f3kat ny\u00fajthatnak a tumor immun-k\u00f6rnyezet\u00e9r\u0151l.<\/span><\/p>\n<p><a href=\"https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image2-scaled.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-52 size-full\" src=\"https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image2-scaled.jpg\" alt=\"\" width=\"2560\" height=\"1672\" srcset=\"https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image2-scaled.jpg 2560w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image2-400x261.jpg 400w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image2-1024x669.jpg 1024w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image2-768x502.jpg 768w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image2-1536x1003.jpg 1536w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image2-2048x1338.jpg 2048w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image2-753x492.jpg 753w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/><\/a><\/p>\n<h4><strong>A projekt k\u00f6zponti c\u00e9ljai:<\/strong><\/h4>\n<ol>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\"><span style=\"font-weight: 400; font-size: 14pt;\">Rendelkez\u00e9sre \u00e1ll\u00f3 retrospekt\u00edv \u00e9s prospekt\u00edv t\u00fcd\u0151tumoros (nem-kissejtes t\u00fcd\u0151r\u00e1k, NSCLC \u00e9s kissejtes t\u00fcd\u0151r\u00e1k, SCLC) beteg<\/span><\/span><span style=\"font-weight: 400; font-size: 14pt;\">cohortok formalin-fix\u00e1lt, paraffinba be\u00e1gyazott mint\u00e1ib\u00f3l tissue microarray (TMA)-k k\u00e9sz\u00edt\u00e9se<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">A TME r\u00e9szletes karakteriz\u00e1l\u00e1sa immunhisztok\u00e9mi\u00e1val (IHC) \u00e9s RNAscope assay-ekkel, valamint multiplexing technik\u00e1kkal (Akoya\u2019s Phenocycler, NanoString GeoMx Digital Spatial Profiler)<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">Kifinomult scoring technik\u00e1k kik\u00e9sz\u00edt\u00e9se, sz\u00e1m\u00edt\u00f3g\u00e9pes k\u00e9panal\u00edzis \u00e9s p\u00e1rhuzamos RNS-protein expresszi\u00f3s (spatial biology) adatfeldolgoz\u00e1s<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">Fejlett t\u00f6bbv\u00e1ltoz\u00f3s statisztikai modellek \u00e9s machine learning <\/span>algoritmusok alkalmaz\u00e1sa a prognosztikus \u00e9s predikt\u00edv biomarkerek azonos\u00edt\u00e1hoz<\/li>\n<\/ol>\n<h4>\u00a0<\/h4>\n<h4><strong>Publik\u00e1ci\u00f3ink a t\u00e9m\u00e1ban:<\/strong><\/h4>\n<p><a href=\"https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image1.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-51 \" src=\"https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image1-968x1024.jpg\" alt=\"\" width=\"600\" height=\"635\" srcset=\"https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image1-968x1024.jpg 968w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image1-378x400.jpg 378w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image1-768x812.jpg 768w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image1-1452x1536.jpg 1452w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image1-753x796.jpg 753w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2024\/11\/Image1.jpg 1648w\" sizes=\"auto, (max-width: 600px) 100vw, 600px\" \/><\/a><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Dora D<\/strong>, Megyesfalvi Z, V\u00f6r\u00f6s I, Pa\u00e1l \u00c1, Takacs P, Dobos D, L\u0151rincz B, Bokhari SMZ, Aloss K, Pallag G, Rivard C, Yu H, Hirsch FR, G\u00f6rbe A, Varga ZV, Lohinai Z, Dome B. Expression of costimulatory molecule CD70 is prognostic in small cell lung cancer. Cancer Immunol Immunother. 2025 Apr 9;74(5):165.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><b>Dora, David<\/b><span style=\"font-weight: 400;\"> ; V\u00f6r\u00f6s, Imre ; Varga, Zolt\u00e1n V. ; Takacs, Peter ; Teglasi, Vanda ; Moldvay, Judit ; Lohinai, Zoltan \u2709 BRAF RNA is prognostic and widely expressed in lung adenocarcinoma TRANSLATIONAL LUNG CANCER RESEARCH 12 : 1 pp. 27-41. , 15 p. (2023)<\/span><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><b>Dora, David<\/b><span style=\"font-weight: 400;\"> ; Rivard, Christopher ; Yu, Hui ; Pickard, Shivaun Lueke ; Laszlo, Viktoria; Harko, Tunde ; Megyesfalvi, Zsolt ; Gerdan, Csongor ; Dinya, Elek ; Hoetzenecker, Konrad et al. Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer. CANCER IMMUNOLOGY IMMUNOTHERAPY 72 : 3 pp. 561-578. , 18 p. (2023)<\/span><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><span style=\"font-weight: 400;\">Lohinai, Zoltan ; <\/span><b>Dora, David<\/b><span style=\"font-weight: 400;\"> \u2709 ; Caldwell, Charles ; Rivard, Christopher J. ; Suda, Kenichi ; Yu, Hui ; Rivalland, Gareth ; Ellison, Kim ; Rozeboom, Leslie ; Dziadziuszko, Rafal et al. Loss of STING expression is prognostic in non\u2013small cell lung cancer JOURNAL OF SURGICAL ONCOLOGY 125 : 6 pp. 1042-1052. , 11 p. (2022)<\/span><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><b>Dora, David<\/b><span style=\"font-weight: 400;\"> ; Rivard, Christopher ; Yu, Hui ; Picard, Shivaun Lueke ; Laszlo, Viktoria ; Harko, Tunde ; Megyesfalvi, Zsolt ; Dinya, Elek ; Gerdan, Csongor ; Szegvari, Gabor et al. Characterization of Tumor-associated Macrophages and the Immune Microenvironment in Limited-stage Neuroendocrine High-and -Low Small Cell Lung Cancer BIOLOGY-BASEL 10 : 6 Paper: 502 , 25 p. (2021)<\/span><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><b>David, Dora<\/b><span style=\"font-weight: 400;\"> ; Rivard, Christopher ; Yu, Hui ; Bunn, Paul ; Suda, Kenichi ; Ren, Shengxiang ; Pickard, Shivaun Lueke ; Laszlo, Viktoria ; Harko, Tunde ; Megyesfalvi, Zsolt et al. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution MOLECULAR ONCOLOGY 14 : 9 pp. 1947-1965. , 19 p. (2020)<a id=\"bel-mikrobiom\"><\/a><\/span><\/span><\/p>\n<hr \/>\n<h2>A b\u00e9l mikrobiom hat\u00e1sa a tumorellenes immunit\u00e1sra \u00e9s az immunter\u00e1pi\u00e1ra<\/h2>\n<div class=\"keretes w-100\">\n<p><span style=\"font-weight: 400; font-size: 14pt;\">A t\u00fcd\u0151r\u00e1k a r\u00e1k okozta hal\u00e1loz\u00e1sok egyik vezet\u0151 oka vil\u00e1gszerte (az \u00f6sszes eset 11,6%-a), ahol az immunellen\u0151rz\u0151 pont g\u00e1tl\u00f3 (ICI) monoter\u00e1pi\u00e1t vagy ICI kombin\u00e1ci\u00f3kat gyakran alkalmazz\u00e1k els\u0151vonalbeli kezel\u00e9sk\u00e9nt az el\u0151rehaladott st\u00e1dium\u00fa \u00e9s nem kissejtes t\u00fcd\u0151r\u00e1k (NSCLC) eset\u00e9ben. Jelenleg az 5 \u00e9ves t\u00fal\u00e9l\u00e9si ar\u00e1ny az NSCLC immunter\u00e1pi\u00e1val kezelt betegek k\u00f6r\u00e9ben egyetlen szerrel 30% a biomarkerrel kiv\u00e1lasztott (magas PD-L1 expresszi\u00f3j\u00fa) popul\u00e1ci\u00f3kban, \u00e9s 10-20% a biomarkerrel nem kiv\u00e1lasztott csoportokban.\u00a0<\/span><\/p>\n<\/div>\n<p><span style=\"font-weight: 400; font-size: 14pt;\">Az onkol\u00f3gia vil\u00e1g\u00e1ba m\u00e1ra bef\u00e9rk\u0151z\u00f6tt a mikrobiom kutat\u00e1s is, ugyanis a b\u00e9lmikrobiom egyre t\u00f6bb kutat\u00e1si eredm\u00e9ny alapj\u00e1n k\u00e9pes modul\u00e1lni az immunrendszer r\u00e1kellenes v\u00e1laszait \u00e9s a daganat mikrok\u00f6rnyezet\u00e9t. Er\u0151s bizony\u00edt\u00e9kok utalnak arra, hogy a b\u00e9lben \u00e9l\u0151 bakt\u00e9riumok k\u00f6zvetlen\u00fcl befoly\u00e1solj\u00e1k a gasztrointesztin\u00e1lis tumorok kialakul\u00e1s\u00e1t a diszbi\u00f3zis r\u00e9v\u00e9n, de tanulm\u00e1nyok m\u00e1s, nem b\u00e9lrendszeri r\u00e1kok eset\u00e9ben is kimutattak hasonl\u00f3 \u00f6sszef\u00fcgg\u00e9seket, bele\u00e9rtve a t\u00fcd\u0151r\u00e1kot, amelyben a mi csoportunk is k\u00f6z\u00f6lt kor\u00e1bban kutat\u00e1si eredm\u00e9nyeket. Tov\u00e1bb\u00e1 az ut\u00f3bbi id\u0151ben intenz\u00edven vizsg\u00e1lj\u00e1k a b\u00e9lmikrobiom szerep\u00e9t a daganatellenes v\u00e1laszok k\u00f6zvet\u00edt\u00e9s\u00e9ben, k\u00fcl\u00f6n\u00f6sen az immun- \u00e9s kemoter\u00e1pi\u00e1s kezel\u00e9sek kapcs\u00e1n. A kutat\u00e1si projekt sz\u00e1mos kulcs k\u00e9rd\u00e9sre keresi a v\u00e1laszt: Melyek a t\u00fcd\u0151r\u00e1k immun mikrok\u00f6rnyezet\u00e9nek specifikus jellemz\u0151i, \u00e9s hogyan korrel\u00e1lnak az immunter\u00e1pia hat\u00e1soss\u00e1g\u00e1val \u00e9s a t\u00fal\u00e9l\u00e9ssel? Hogyan korrel\u00e1l a b\u00e9l mikrobiomj\u00e1nak kompoz\u00edci\u00f3ja a tumor mikrok\u00f6rnyezet tulajdons\u00e1gaival \u00e9s a kezel\u00e9si eredm\u00e9nyekkel? Milyen funkcion\u00e1lis \u00e1llapotban vannak az immunsejtek a tumor mikrok\u00f6rnyezetben, \u00e9s van-e \u00f6sszef\u00fcgg\u00e9s k\u00f6zt\u00fck \u00e9s mikrobiom k\u00f6z\u00f6tt? A k\u00fcl\u00f6nb\u00f6z\u0151 lymphocyta-diszfunkci\u00f3k \u00f6sszef\u00fcgg\u00e9sbe hozhat\u00f3k-e egy specifikus taxon\u00f3miai vagy metabolikus b\u00e9l- vagy intratumor\u00e1lis mikrobiommal? K\u00e9pesek-e az \u00faj mikrobi\u00e1lis biomarkerek el\u0151re jelezni a beteg v\u00e1lasz\u00e1t az immunter\u00e1pi\u00e1ra?<\/span><\/p>\n<p><span style=\"font-weight: 400; font-size: 14pt;\">A kutat\u00e1s c\u00e9lja \u00faj predikt\u00edv \u00e9s prognosztikus biomarkerek felfedez\u00e9se a tumor mikrok\u00f6rnyezetben \u00e9s a b\u00e9l mikrobiomban, amelyek el\u0151seg\u00edtik ezek interakci\u00f3inak meg\u00e9rt\u00e9s\u00e9t. Az\u00e1ltal, hogy betekint\u00e9st ny\u00fajtunk abba, hogyan befoly\u00e1solj\u00e1k a b\u00e9l- \u00e9s intratumor\u00e1lis mikr\u00f3b\u00e1k az anti-tumor immunit\u00e1st \u00e9s a daganatok progresszi\u00f3j\u00e1t, ez a kutat\u00e1s \u00faj t\u00e1vlatokat nyithat a mikrobiom-alap\u00fa r\u00e1kter\u00e1pi\u00e1k sz\u00e1m\u00e1ra.\u00a0<\/span><\/p>\n<h4>\u00a0<\/h4>\n<h4><strong>A projekt k\u00f6zponti c\u00e9ljai:<\/strong><\/h4>\n<ol>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">A tumor mikrok\u00f6rnyezet multiplex m\u00f3dszerekkel val\u00f3 karakteriz\u00e1l\u00e1s\u00e1b\u00f3l sz\u00e1rmaz\u00f3 \u201cspatial biology\u201d adatok b\u00e9lmikrobiommal val\u00f3 korrel\u00e1ci\u00f3ja\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">Az intratumor\u00e1lis mikrobiom anal\u00edzise \u00e9s annak korrel\u00e1ci\u00f3ja a b\u00e9lmikrobiommal, tumor mikrok\u00f6rnyezettel \u00e9s a betegek ter\u00e1pi\u00e1s v\u00e1lasz\u00e1val<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">In vitro \u00e9s eg\u00e9rk\u00eds\u00e9rletek a statisztikailag kimutatott \u00f6sszef\u00fcgg\u00e9sek valid\u00e1ci\u00f3j\u00e1ra<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">Mikrobi\u00e1lis adjuv\u00e1ns immunter\u00e1pi\u00e1k kifejleszt\u00e9se, azok preklinikai tesztel\u00e9se tumoros eg\u00e9rmodelleken<\/span><\/li>\n<\/ol>\n<h4><a href=\"https:\/\/semmelweis.hu\/tumorimmune\/files\/2026\/03\/Gut_lung_rev.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-172 size-full\" src=\"https:\/\/semmelweis.hu\/tumorimmune\/files\/2026\/03\/Gut_lung_rev.png\" alt=\"\" width=\"1536\" height=\"1024\" srcset=\"https:\/\/semmelweis.hu\/tumorimmune\/files\/2026\/03\/Gut_lung_rev.png 1536w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2026\/03\/Gut_lung_rev-400x267.png 400w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2026\/03\/Gut_lung_rev-1024x683.png 1024w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2026\/03\/Gut_lung_rev-768x512.png 768w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2026\/03\/Gut_lung_rev-753x502.png 753w, https:\/\/semmelweis.hu\/tumorimmune\/files\/2026\/03\/Gut_lung_rev-203x135.png 203w\" sizes=\"auto, (max-width: 1536px) 100vw, 1536px\" \/><\/a><\/h4>\n<h4>\u00a0<\/h4>\n<h4><span style=\"font-family: Montserrat;\"><strong>Publik\u00e1ci\u00f3ink a t\u00e9m\u00e1ban:<\/strong><\/span><\/h4>\n<p>Somodi C, <strong>Dora D<\/strong>, Horv\u00e1th M, Szegvari G, Lohinai Z. Gut microbiome changes and cancer immunotherapy outcomes associated with dietary interventions: a systematic review of preclinical and clinical evidence. JOURNAL OF TRANSLATIONAL MEDICINE. 2025 Jul 8;23(1):756.\u00a0<\/p>\n<p><strong>Dora D<\/strong>, Revisnyei P, Pasic A, Galffy G, Dulka E, Mihucz A, Rosk\u00f3 B, Szincsak S, Iliuk A, Weiss GJ, Lohinai Z. Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients. FRONTIERS IN IMMUNOLOGY. 2025 Apr 14;16:1543817.<\/p>\n<p><strong>Dora, David<\/strong>., Kiraly, P., Somodi, C. Balazs, Ligeti; Edit, Dulka; Gabriella, Galffy; Zoltan, Lohinai <span style=\"font-size: 14pt;\"><span style=\"font-weight: 400;\">\u2709<\/span><\/span>. Gut metatranscriptomics based de novo assembly reveals microbial signatures predicting immunotherapy outcomes in non-small cell lung cancer. JOURNAL OF TRANSLATIONAL MEDICINE 22, 1044 (2024).\u00a0<\/p>\n<p><span style=\"font-size: 14pt;\"><b>Dora, David<\/b><span style=\"font-weight: 400;\"> \u2709 ; Sz\u0151cs, Em\u0151ke; So\u00f3s, \u00c1d\u00e1m; Halasy, Vikt\u00f3ria; Somodi, Csenge; Mihucz, Anna; Rost\u00e1s, Melinda; M\u00f3gor, Fruzsina; Lohinai, Zoltan; Nagy, N\u00e1ndor <\/span>From bench to bedside: an interdisciplinary journey through the gut-lung axis with insights into lung cancer and immunotherapy FRONTIERS IN IMMUNOLOGY 15 Paper: 1434804 , 29 p. (2024)<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><b>David, Dora<\/b><span style=\"font-weight: 400;\"> ; Balazs, Ligeti ; Tamas, Kovacs ; Peter, Revisnyei ; Gabriella, Galffy ; Edit, Dulka ; D\u00e1niel, Krizs\u00e1n ; Regina, Kalcsevszki ; Zsolt, Megyesfalvi ; Balazs, Dome \u2709 ; Zoltan, Lohinai \u2709. Non-Small Cell Lung Cancer Patients Treated with Anti-PD1 Immunotherapy Show Distinct Microbial Signatures and Metabolic Pathways According to Progression-free Survival and PD-L1 status ONCOIMMUNOLOGY 12 : 1 Paper: 2204746 , 15 p. (2023)<\/span><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><b>Dora, David<\/b><span style=\"font-weight: 400;\">; Weiss, Glen J; Megyesfalvi, Zsolt; G\u00e1llfy, Gabriella; Dulka, Edit; Kerpel-Fronius, Anna; Berta, Judit; Moldvay, Judit; Dome, Balazs \u2709 ; Lohinai, Zoltan \u2709 Computed Tomography-Based Quantitative Texture Analysis and Gut Microbial Community Signatures Predict Survival in Non-Small Cell Lung Cancer. <\/span><span style=\"font-weight: 400;\">CANCERS 15 : 20 Paper: 5091 , 19 p. (2023)<\/span><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><b>D\u00f3ra, D\u00e1vid<\/b><span style=\"font-weight: 400;\"> \u2709; Bokhari, Syeda Mahak Zahra; Aloss, Kenan; Tak\u00e1cs, P\u00e9ter; Desnoix, Juliane Zsuzsanna; Szklen\u00e1rik, Gy\u00f6rgy; Hurley, Patrick Deniz; Lohinai, Zolt\u00e1n \u2709 Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 24 : 3 Paper: 2769 , 26 p. (2023)<\/span><\/span><\/p>\n<h4>\u00a0<\/h4>\n<h4><strong>K\u00f6nyvfejezet:<\/strong><\/h4>\n<p><span style=\"font-size: 14pt;\"><b>D\u00f3ra, D<\/b><span style=\"font-weight: 400;\">. A b\u00e9lidegrendszer: b\u00e9l-agy tengely In: Tulassay, Zsolt (szerk.) Gasztroenterol\u00f3gia <\/span><span style=\"font-weight: 400;\">Budapest, Magyarorsz\u00e1g : Medicina K\u00f6nyvkiad\u00f3 (2023) 1,180 p. pp. 14-23. , 10 p.<a id=\"eszkozok\"><\/a><\/span><\/span><\/p>\n<hr \/>\n<h2>Eszk\u00f6z\u00f6k, m\u00f3dszerek<\/h2>\n<ol>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">Immunhisztok\u00e9mia (IHC), Immuncitok\u00e9mia (ICC), Immunfluoreszcencia (IF) fagyasztott \u00e9s formalin-fix\u00e1lt paraffinba \u00e1gyazott (FFPE) metszeteken<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">RNAscope, RNAscope &#8211; IF multiplexing fagyasztott \u00e9s FFPE metszeteken<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">Rutin sz\u00f6vettani el\u0151k\u00e9sz\u00edt\u00e9s, tissue-microarray (TMA)-k tervez\u00e9se \u00e9s k\u00e9sz\u00edt\u00e9s\u00fckben val\u00f3 r\u00e9szv\u00e9tel<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">Fejlett mikroszk\u00f3pos scoring rendszerek fejleszt\u00e9se, haszn\u00e1lata. Sz\u00e1m\u00edt\u00f3g\u00e9pes k\u00e9panal\u00edzis, morfometria kromog\u00e9nnel \u00e9s fluoreszcensen festett metszeteken. Konfok\u00e1lis mikroszk\u00f3pia \u00e9s k\u00e9panal\u00edzis<\/span><\/li>\n<li>Multimod\u00e1lis spatial biology adatok elemz\u00e9se QuPath \u00e9s ImageJ szoftvercsomagokkal.\u00a0<\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">Mikrobiom szekven\u00e1l\u00e1si adat elemz\u00e9s (Metagenome, metatranszkriptome). Nyers abundancia m\u00e1trixok el\u0151\u00e1ll\u00edt\u00e1sa, normaliz\u00e1l\u00e1s, taxon\u00f3miai \u00e9s diverzit\u00e1s anal\u00edzis. Metabolikus \u00e9s transzkriptomikai pathway anal\u00edzis MetaPhlan, Humann, Kraken \u00e9s de novo assembly pipeline-ok haszn\u00e1lat\u00e1val. Adatvizualiz\u00e1ci\u00f3 \u00e9s magas szint\u0171 statisztikai modellek \u00e9p\u00edt\u00e9se. Machine learning.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">Klinikai betegadat kezel\u00e9s, adatb\u00e1zis \u00e9p\u00edt\u00e9s, adat menedzsment<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400; font-size: 14pt;\">Eg\u00e9rk\u00eds\u00e9rletek, azok el\u0151k\u00e9sz\u00edt\u00e9se \u00e9s eg\u00e9r szervek, sz\u00f6vetek elt\u00e1vol\u00edt\u00e1sa, feldolgoz\u00e1sa hisztol\u00f3giai \u00e9s downstream molekul\u00e1ris anal\u00edzis c\u00e9lj\u00e1b\u00f3l<\/span><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Tartalomjegyz\u00e9k: <a href=\"#tumor-mikrokornyezet\">Tumor mikrok\u00f6rnyezet felt\u00e9rk\u00e9pez\u00e9se in situ technik\u00e1kkal t\u00fcd\u0151r\u00e1kban<\/a> <a href=\"#bel-mikrobiom\">A b\u00e9l mikrobiom hat\u00e1sa a tumorellenes immunit\u00e1sra \u00e9s az immunter\u00e1pi\u00e1ra<\/a> <a href=\"#eszkozok\">Eszk\u00f6z\u00f6k, m\u00f3dszerek<\/a> <a id=\"tumor-mikrokornyezet\"><\/a> Tumor mikrok\u00f6rnyezet felt\u00e9rk\u00e9pez\u00e9se in situ technik\u00e1kkal t\u00fcd\u0151r\u00e1kban A t\u00fcd\u0151r\u00e1k \u00e9s annak leggyakoribb v\u00e1ltozata, a nem kissejtes t\u00fcd\u0151r\u00e1k (NSCLC), tov\u00e1bbra is az egyik vezet\u0151 hal\u00e1lok a daganatos betegs\u00e9gek k\u00f6z\u00f6tt vil\u00e1gszerte. Az immunter\u00e1pi\u00e1k, k\u00fcl\u00f6n\u00f6sen az immunellen\u0151rz\u0151pont-g\u00e1tl\u00f3k (ICI) ter\u00e9n el\u00e9rt el\u0151rel\u00e9p\u00e9sek ellen\u00e9re a jelenlegi kezel\u00e9sek hat\u00e9konys\u00e1ga korl\u00e1tozott, \u00e9s a megl\u00e9v\u0151 biomarkerek, mint a PD-L1 expresszi\u00f3 \u00e9s a &hellip;<\/p>\n","protected":false},"author":101680,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-44","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/tumorimmune\/wp-json\/wp\/v2\/pages\/44","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/tumorimmune\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/semmelweis.hu\/tumorimmune\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/tumorimmune\/wp-json\/wp\/v2\/users\/101680"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/tumorimmune\/wp-json\/wp\/v2\/comments?post=44"}],"version-history":[{"count":10,"href":"https:\/\/semmelweis.hu\/tumorimmune\/wp-json\/wp\/v2\/pages\/44\/revisions"}],"predecessor-version":[{"id":206,"href":"https:\/\/semmelweis.hu\/tumorimmune\/wp-json\/wp\/v2\/pages\/44\/revisions\/206"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/tumorimmune\/wp-json\/wp\/v2\/media?parent=44"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/tumorimmune\/wp-json\/wp\/v2\/categories?post=44"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/tumorimmune\/wp-json\/wp\/v2\/tags?post=44"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}